IQVIA (NYSE:IQV) Price Target Raised to $287.00

IQVIA (NYSE:IQV) had its target price upped by Robert W. Baird from $252.00 to $287.00 in a research report released on Wednesday morning, MarketBeat Ratings reports. Robert W. Baird currently has an outperform rating on the medical research company’s stock.

Other equities analysts have also recently issued reports about the stock. Evercore restated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Barclays reiterated an “overweight” rating on shares of IQVIA in a research report on Tuesday. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research note on Thursday, July 9th. Finally, Mizuho lifted their price target on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $241.88.

IQVIA Stock Performance

IQV opened at $235.09 on Wednesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.75 and a current ratio of 0.71. IQVIA has a 52-week low of $154.50 and a 52-week high of $251.36. The firm has a market cap of $38.70 billion, a P/E ratio of 29.17, a price-to-earnings-growth ratio of 2.01 and a beta of 1.20. The business’s fifty day moving average is $194.75 and its 200-day moving average is $187.20.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts expect that IQVIA will post 11.6 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s management believes its stock is undervalued.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the transaction, the insider directly owned 20,999 shares in the company, valued at approximately $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares of the company’s stock, valued at $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On IQVIA

Large investors have recently bought and sold shares of the company. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA in the fourth quarter valued at approximately $25,000. Financial Freedom LLC bought a new position in IQVIA in the 1st quarter valued at approximately $25,000. Ascentis Independent Advisors bought a new stake in IQVIA during the 1st quarter worth approximately $25,000. International Assets Investment Management LLC bought a new stake in IQVIA during the 4th quarter worth approximately $27,000. Finally, Gilpin Wealth Management LLC bought a new position in shares of IQVIA during the fourth quarter valued at $27,000. 89.62% of the stock is currently owned by institutional investors.

Key Stories Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: William Blair upgraded IQVIA to “strong buy,” adding to the favorable analyst outlook. Ticker Report article
• Positive Sentiment: Robert W. Baird raised its IQVIA price target to $287, implying substantial upside from the cited trading level. JPMorgan and Stifel Nicolaus also expressed expectations for further appreciation. American Banking News article on Baird price target American Banking News article on JPMorgan forecast American Banking News article on Stifel outlook
• Positive Sentiment: IQVIA’s second-quarter results exceeded expectations, with adjusted earnings of $3.15 per share versus the $3.03 consensus and revenue of $4.37 billion versus $4.30 billion expected. Revenue increased 8.7% year over year, reinforcing the company’s growth profile. IQVIA Q2 2026 earnings call summary
• Neutral Sentiment: Analysts maintain a “moderate buy” consensus, indicating generally favorable sentiment but not unanimous conviction. IQVIA analyst consensus article
• Negative Sentiment: Two insiders sold shares on July 29: Keriann Cherofsky sold 558 shares for approximately $136,827, while Eric Sherbet sold 5,000 shares for about $1.25 million. Although both retain meaningful holdings, the transactions may create short-term investor concern. SEC insider sale filing for Keriann Cherofsky SEC insider sale filing for Eric Sherbet

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.